Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Table 6 Comparison of tumor indexes between programmed cell death 1 + S-1 + oxaliplatin group and S-1 + oxaliplatin group before and after chemotherapy

	P-SOX group (n = 28)			SOX group (n = 61)
	First diagnosed	Preoperative	P value	First diagnosed	Preoperative	P value
AFP (ng/mL)			0.019a			0.002a
≤ 8.1	20 (71.43%)	20 (71.43%)		43 (70.49%)	46 (75.41%)
> 8.1	2 (7.14%)	4 (14.29%)		8 (13.11%)	11 (18.03%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CEA (ng/mL)			0.211			0.405
≤ 5	16 (57.14%)	22 (57.14%)		35 (57.38%)	43 (70.49%)
> 5	6 (21.43%)	2 (21.43%)		16 (26.23%)	14 (22.95%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA199 (U/mL)			0.232			0.181
≤ 37	16 (57.14%)	22 (57.14%)		36 (59.02%)	49 (80.33%)
> 37	6 (21.43%)	2 (21.43%)		15 (24.59%)	8 (13.11%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA724 (U/mL)			0.356			0.552
≤ 6.9	12 (42.86%)	18 (42.86%)		32 (52.46%)	32 (52.46%)
> 6.9	10 (35.71%)	6 (35.71%)		19 (31.15%)	23 (37.70%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	6 (9.84%)
CA125 (U/mL)			0.005a			0.023a
≤ 35	13 (46.43%)	23 (82.14%)		42 (68.85%)	54 (88.52%)
> 35	9 (32.14%)	1 (3.57%)		9 (14.75%)	3 (4.92%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA50 (U/mL)			0.301			0.915
≤ 25	18 (64.29%)	22 (64.29%)		42 (68.85%)	47 (77.05%)
> 25	4 (14.29%)	2 (14.29%)		9 (14.75%)	8 (13.11%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	6 (9.84%)
Leukemia			0.366			0.005a
≤ 3.5	1 (3.57%)	7 (25%)		3 (4.92%)	12 (19.67%)
3.5-9.5	19 (67.86%)	16 (57.14%)		43 (70.49%)	43 (70.49%)
> 9.5	3 (10.71%)	3 (10.71%)		5 (8.20%)	4 (6.56%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
HGB			0.094			0.045a
≤ 130	18 (64.29%)	23 (82.14%)		36 (59.02%)	48 (78.69%)
130-175	5 (8.20%)	3 (10.71%)		15 (24.59%)	11 (18.03%)
> 175	0	0		0	0
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
Platelets			0.001a			0.001a
≤ 125	2 (7.14%)	7 (25%)		2 (3.28%)	21 (34.43%)
125-350	16 (57.14%)	19 (67.86%)		39 (63.93%)	35 (57.38%)
> 350	5 (8.20%)	0		10 (16.39%)	3 (4.92%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
Neutrophils			0.077			0.005a
≤ 1.8	1 (3.57%)	6 (21.43%)		4 (6.56%)	13 (21.31%)
1.9-6.3	18 (64.29%)	17 (60.71%)		41 (67.21%)	42 (68.85%)
> 6.3	4 (14.29%)	3 (10.71%)		6 (9.84%)	4 (6.56%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199; HGB: Hemoglobin.